![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
December 12, 2024
December 10, 2024
Posts
#ClinicalTrial EA4231, led by @MelanicjMD of @theNCI, is testing the effectiveness of a combination #TargetedTherapy for patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment. For more info: https://bit.ly/EA4231 cc: @LLSusa, @lymphomahub
#Clinicaltrial EA8192 aims to find out if treatment with durvalumab and chemotherapy can improve outcomes for patients with high grade upper tract #urothelialcancer prior to nephroureterectomy. https://bit.ly/ea8192-trial #blcsm #bladdercancer cc: @JCensits, @PGrivasMDPhD
Do you have advanced #cancer that has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: http://bit.ly/ComboMATCH
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
38
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
